Official Title
Efficacy and Safety of Darunavir/Cobicistat vs. Lopinavir/Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar
Brief Summary

Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. It was first isolated in Wuhan, China in December 2019 and then rapidly spread to the rest of the world posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes. Protease inhibitors are one of the proposed agents, but their use is limited to their significant drug interactions and side effects. The aim of this study is to compare the efficacy and safety outcomes of Darunavir/Cobicistat versus Lopinavir /Ritonavir in the treatment of patients with COVID-19 pneumonia in Qatar.

Completed
Coronavirus
COVID
Pneumonia

Drug: Darunavir/Cobicistat

Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily

Drug: Lopinavir/Ritonavir

Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily

Eligibility Criteria

Inclusion Criteria:

- Adult patients ≥18 years of age

- Laboratory confirmed 2019-nCoV infection as determined by the PCR of the
nasopharyngeal/oropharyngeal swab.

- Radiologically confirmed pneumonia (Based on the chest x-ray or CT scan imaging).

- Have received either Darunavir/Cobicistat or Lopinavir/Ritonavir as part of the
treatment regimen for COVID-19 pneumonia

Exclusion Criteria:

- No exclusion criteria will be applied

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Qatar
Locations

Hamad Medical Corporation
Doha, Qatar

Dr. Eman Elmekaty, PharmD, Principal Investigator
Hamad Medical Corporation

Hamad Medical Corporation
NCT Number
MeSH Terms
Pneumonia
Ritonavir
Lopinavir
Darunavir
Cobicistat
Cobicistat mixture with darunavir